Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8101 to 8150 of 8905 results

  1. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

    Withdrawn guidance

  2. Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA620)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Withdrawn guidance

  3. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 654 

    Withdrawn guidance

  4. Sotagliflozin with insulin for treating type 1 diabetes (TA622)

    NICE has withdrawn this guidance. This is because the company is no longer marketing sotagliflozin (Zynquista) and its marketing authorisation has been withdrawn.  

    Withdrawn guidance

  5. Glitazones in the treatment of type 2 diabetes (TA63)

    This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).

    Withdrawn guidance

  6. Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1118. People already having entrectinib for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours through the Cancer Drugs Fund will be able to continue until they and their healthcare professional decide when best to stop.

    Withdrawn guidance

  7. Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1120.

    Withdrawn guidance

  8. Guidance on the use of photodynamic therapy for age-related macular degeneration (TA68)

    This guidance has been updated and replaced by NICE guideline NG82.

    Withdrawn guidance

  9. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA1007.

    Withdrawn guidance

  10. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613)

    This guidance has been updated and replaced by NICE technology appraisal guidance 953.

    Withdrawn guidance

  11. Fremanezumab for preventing migraine (TA631)

    This guidance has been updated and replaced by NICE technology appraisal guidance 764.

    Withdrawn guidance

  12. Teduglutide for treating short bowel syndrome (terminated appraisal) (TA690)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA804.

    Withdrawn guidance

  13. Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (TA693)

    This guidance has been updated and replaced by NICE technology appraisal guidance 946.

    Withdrawn guidance

  14. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)

    This guidance has been updated and replaced by NICE technology appraisal guidance 984.

    Withdrawn guidance

  15. The clinical and cost effectiveness of proton pump inhibitors for the treatment of dyspepsia (TA7)

    This guidance has been replaced by NICE guideline CG17. [Replaced by NICE guideline CG184]

    Withdrawn guidance

  16. Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal) (TA700)

    This guidance has been updated and replaced by NICE technology appraisal guidance 970 and NICE technology appraisal guidance 974.  

    Withdrawn guidance

  17. Rituximab for aggressive non-Hodgkin's lymphoma (TA65)

    After consultation the guidance has been withdrawn because it is no longer relevant to clinical practice. Rituximab is now routinely used outside its licensed indication. See NICE’s guideline on non-Hodgkin’s lymphoma.

    Withdrawn guidance

  18. Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) (TA652)

    This guidance has been updated and replaced by NICE technology appraisal guidance 816.

    Withdrawn guidance

  19. The clinical effectiveness and cost effectiveness of new drugs for bipolar disorder (TA66)

    This guidance has been updated and replaced NICE guideline CG38.

    Withdrawn guidance

  20. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1119.

    Withdrawn guidance

  21. Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies (TA669)

    This guidance has been updated and replaced by NICE technology appraisal guidance 852.

    Withdrawn guidance

  22. The clinical effectiveness and cost effectiveness of amantadine and oseltamivir for the prophylaxis of influenza (TA67)

    This guidance has been updated and replaced NICE technology appraisal guidance 158.

    Withdrawn guidance

  23. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA711)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA815.

    Withdrawn guidance

  24. FebriDx for C-reactive protein and Myxovirus resistance protein A testing in primary care (MIB114)

    This advice has been updated and replaced by NICE medtech innovation briefing 224.

    Withdrawn advice

  25. Mepilex Border dressings for preventing pressure ulcers (MIB124)

    This advice has been updated and replaced by NICE medical technologies guidance 40.

    Withdrawn advice

  26. Promonitor for monitoring response to biologics in rheumatoid arthritis (MIB126)

    This advice has been replaced by NICE HealthTech guidance 521.

    Withdrawn advice

  27. Health app: Sleepio for adults with poor sleep (MIB129)

    This advice has been updated and replaced by NICE healthtech guidance 624.

    Withdrawn advice

  28. Health app: ChatHealth communication platform in school nursing services (MIB130)

    The health app briefing on ChatHealth communication platform in school nursing services has been withdrawn.

    Withdrawn advice

  29. Health app: GDm-Health for people with gestational diabetes (MIB131)

    This health app briefing on GDm-Health for people with gestational diabetes has been withdrawn.

    Withdrawn advice

  30. Point-of-care creatinine tests before contrast-enhanced imaging (MIB136)

    This advice has been replaced by NICE HealthTech guidance 530.

    Withdrawn advice

  31. Zio Service for detecting cardiac arrhythmias (MIB101)

    This advice has been updated and replaced by NICE healthtech guidance 562.

    Withdrawn advice

  32. Ectopic pregnancy and miscarriage: diagnosis and initial management (CG154)

    This guidance has been updated and replaced by NICE guideline NG126

    Withdrawn guideline

  33. Chronic kidney disease (stage 4 or 5): management of hyperphosphataemia (CG157)

    This guidance has been updated and replaced by NICE guideline NG203.

    Withdrawn guideline

  34. Ulcerative colitis: management (CG166)

    This guidance has been updated and replaced by NICE guideline NG130.

    Withdrawn guideline

  35. Myocardial infarction with ST-segment elevation: acute management (CG167)

    This guideline has been updated and replaced by NICE guideline NG185.

    Withdrawn guideline

  36. Acute kidney injury: prevention, detection and management (CG169)

    This guidance has been updated and replaced by NICE guideline NG148.

    Withdrawn guideline

  37. Dyspepsia: Management of dyspepsia in adults in primary care (CG17)

    This guidance has been updated and replaced by NICE guideline CG184.

    Withdrawn guideline

  38. Urinary incontinence in women: management (CG171)

    This guideline has been updated and replaced by NICE guideline NG123.

    Withdrawn guideline

  39. Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease (CG172)

    This guideline has been updated and replaced by NICE guideline NG185.

    Withdrawn guideline

  40. Chronic heart failure: Management of chronic heart failure in adults in primary and secondary care (CG5)

    This guideline has been updated and replaced by NICE guideline CG108.

    Withdrawn guideline

  41. Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management (CG53)

    This guideline has been updated and replaced by NICE guideline NG206.

    Withdrawn guideline

  42. Urinary tract infection in under 16s: diagnosis and management (CG54)

    This guidance has been updated and replaced by NICE guideline NG224.

    Withdrawn guideline

  43. Intrapartum care: Care of healthy women and their babies during childbirth (CG55)

    This guidance has been updated and replaced by NICE guideline CG190.

    Withdrawn guideline

  44. Head injury: Triage, assessment, investigation and early management of head injury in infants, children and adults (CG56)

    This guidance has been updated and replaced by NICE guideline CG176.

    Withdrawn guideline

  45. Infection control: prevention of healthcare-associated infection in primary and community care (CG2)

    This guidance has been updated and replaced by NICE guideline CG139.    

    Withdrawn guideline

  46. The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care (CG20)

    This guideline has been updated and replaced by NICE guideline CG137.

    Withdrawn guideline

  47. Falls: the assessment and prevention of falls in older people (CG21)

    This guideline has been updated and replaced by NICE guideline CG161.

    Withdrawn guideline

  48. Anxiety: Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care (CG22)

    This guideline has been updated and replaced by NICE guideline CG113.

    Withdrawn guideline

  49. Depression: management of depression in primary and secondary care (CG23)

    This guidance has been updated and replaced by NICE guideline CG90.

    Withdrawn guideline

  50. Lung cancer: diagnosis and treatment (CG24)

    This guideline has been updated and replaced by NICE guideline CG121.

    Withdrawn guideline